Home

Honnête Exigences rive inventiva press release espion Égocentrique Appliquer

Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial of lanifibrano
Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial of lanifibrano

Inventiva Pharma on LinkedIn: #pressrelease #biotech #lanifibranor #liverdisease #nash #diabetes…
Inventiva Pharma on LinkedIn: #pressrelease #biotech #lanifibranor #liverdisease #nash #diabetes…

INVENTIVA PRESS RELEASE – Bellofox
INVENTIVA PRESS RELEASE – Bellofox

Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results
Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results

Inventiva reports 2022 First Quarter Financial Information1 and provides clinical development update
Inventiva reports 2022 First Quarter Financial Information1 and provides clinical development update

Inventiva reports its 2022 first-half financial results and provides a corporate update
Inventiva reports its 2022 first-half financial results and provides a corporate update

Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor
Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor

Inventiva Pharma sur LinkedIn : #pressrelease #nash #clinicaltrial #lanifibranor #biotech #cirrhosis
Inventiva Pharma sur LinkedIn : #pressrelease #nash #clinicaltrial #lanifibranor #biotech #cirrhosis

Home - Inventiva Pharma
Home - Inventiva Pharma

Combined General Meeting of January 25, 2023 Availability of the preparatory documents
Combined General Meeting of January 25, 2023 Availability of the preparatory documents

Statement of total voting rights and shares forming the company's share capital as of December 19, 2022
Statement of total voting rights and shares forming the company's share capital as of December 19, 2022

Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results
Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results

DESCRIPTION OF THE SHARE REPURCHASE PROGRAM AUTHORISED BY THE ORDINARY GENERAL MEETING OF 19 MAY 2022
DESCRIPTION OF THE SHARE REPURCHASE PROGRAM AUTHORISED BY THE ORDINARY GENERAL MEETING OF 19 MAY 2022

Inventiva reports 2021 first half financial results and provides a corporate update
Inventiva reports 2021 first half financial results and provides a corporate update

Inventiva réalise une augmentation de capital de 15 M€ souscrite par des actionnaires existants - Inventiva Pharma
Inventiva réalise une augmentation de capital de 15 M€ souscrite par des actionnaires existants - Inventiva Pharma

Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiation
Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiation

Inventiva selected to present the results of its NATIVE Phase IIb clinical trial with lanifibranor in NASH during a plenary sess
Inventiva selected to present the results of its NATIVE Phase IIb clinical trial with lanifibranor in NASH during a plenary sess

Odiparcil development advances with recruitment of first patients in a new biomarker study in MPS VI children and adults
Odiparcil development advances with recruitment of first patients in a new biomarker study in MPS VI children and adults

Inventiva announces filing of its 2021 Universal Registration Document and 2021 Annual Report on Form 20-F
Inventiva announces filing of its 2021 Universal Registration Document and 2021 Annual Report on Form 20-F

Inventiva announces the pricing of its initial public offering on the Nasdaq Global Market
Inventiva announces the pricing of its initial public offering on the Nasdaq Global Market

DESCRIPTION OF THE SHARE REPURCHASE PROGRAM AUTHORISED BY THE ORDINARY GENERAL MEETING OF 25 MAY 2023
DESCRIPTION OF THE SHARE REPURCHASE PROGRAM AUTHORISED BY THE ORDINARY GENERAL MEETING OF 25 MAY 2023

Inventiva reports preliminary financial results for Full-Year 2022¹
Inventiva reports preliminary financial results for Full-Year 2022¹

Inventiva : information financière du 3ème trimestre 2017
Inventiva : information financière du 3ème trimestre 2017

2019 Full-Year Results: Significant progress in NASH, MPS VI and psoriasis, and extended cash runway
2019 Full-Year Results: Significant progress in NASH, MPS VI and psoriasis, and extended cash runway

Inventiva annonce la mise en œuvre d'un contrat de liquidité avec Oddo & Cie
Inventiva annonce la mise en œuvre d'un contrat de liquidité avec Oddo & Cie